Akso Health Group filings document the disclosures of a foreign private issuer that files annual reports on Form 20-F and furnishes current reports on Form 6-K. Recent filings include unaudited interim consolidated financial statements, operating and financial review materials, and incorporation of those materials into registration statements on Form S-8 and Form F-3.
The company’s regulatory reports also cover board and committee governance, including changes to independent director roles on the audit, compensation, and nominating and corporate governance committees. The filings frame Akso Health’s public-company reporting around financial position, operating review, capital-market registrations, and governance disclosures.
Akso Health Group reported a change in its independent auditor. Effective May 12, 2026, the company dismissed Onestop Assurance PAC and appointed CHI-LLTC as its new independent registered public accounting firm. The prior auditor’s reports for the fiscal years ended March 31, 2024 and 2025 contained no adverse opinions or qualifications, and the company states there were no disagreements or reportable events during that period.
Akso Health Group director Xie Zhongliang has filed an initial Form 3, which is the first statement of beneficial ownership for a company insider. This filing establishes his status as a director and, in this excerpt, does not report any insider transactions or derivative positions.
Akso Health Group director Xu Jianqiang has filed an initial statement of beneficial ownership on Form 3. The filing lists him as a director but shows no reportable transactions, no derivative positions and no share holdings in the summarized data at this time.
Akso Health Group director files initial ownership report
Akso Health Group director Liu Wenjuan has filed an initial statement of beneficial ownership as required for new insiders. The filing shows no reported purchases, sales, gifts, or other transactions, and no derivative positions are listed in this excerpt.
Akso Health Group reports that independent director Gerald T. Neal resigned from the board effective February 28, 2026 for personal reasons, with no disagreement related to the company’s operations or policies. The board appointed Jianqiang Xu as a new independent director effective March 16, 2026, also naming him to the audit, compensation (as chair), and nominating & corporate governance committees.
Xu is a senior neurosurgeon and hospital administrator in China with extensive clinical and academic experience. Under his director offer letter, he will receive $12,000 per year in cash compensation, paid quarterly, plus reimbursement of reasonable expenses, and is subject to confidentiality, non‑competition and non‑solicitation covenants, as well as indemnification provisions.
Akso Health Group director Stephen P. Brown has filed an initial Form 3, formally disclosing his status as a director of the company. The excerpt shows no reported share transactions or derivative positions, indicating this filing is primarily administrative and focused on establishing insider reporting status.
Akso Health Group director Wang Yilin has filed an initial statement of beneficial ownership on Form 3. This filing establishes Wang Yilin’s reporting status as a director of Akso Health Group but does not list any reportable transactions or holdings in this excerpt.
Akso Health Group director Liu Zhe submitted an initial insider ownership report on Form 3. The filing lists Liu as a director but shows no reported transactions, meaning it simply establishes Liu’s status as an insider for future ownership and trading disclosures.
Akso Health Group filed a Form 6-K furnishing unaudited results for the six months ended September 30, 2025. Net revenues were $6.99M, up slightly from $6.93M, and now come entirely from marketing promotion services after medical device sales dropped to zero.
Gross profit rose to $0.62M, lifting gross margin to 8.9% from 2.8%, but general and administrative expenses nearly tripled to $2.06M, leading to a net loss of $1.30M versus a $0.55M loss a year earlier. Basic and diluted loss per share stayed at $0.001.
Cash and cash equivalents fell sharply to $11.1M from $176.2M at March 31, 2025, as the company used $166.4M in investing cash flow, mainly $175.7M of advances for capital expenditures tied to building its Internet Hospital business platform. Total equity was $198.3M against liabilities of $13.7M. Management cites existing cash and committed support from its controlling shareholder as sufficient to fund operations for at least the next twelve months despite an accumulated deficit of $200.2M.
Akso Health Group (AHG) presents a wide-ranging annual report describing a company transitioning from prior microlending activities into an "Internet+healthcare" and social e-commerce model while pursuing medical device sales, online consultations, community health stations and cancer therapy centers. The company reported higher sales and marketing spend of US$168,421 for the year ended March 31, 2024 versus US$6,661 the prior year driven by brand-building for new businesses, and a reduction in general and administrative expenses to US$8.6 million (down 44.7% from US$15.5 million) primarily due to lower provisions for uncollected receivables. The report discloses net income from discontinued operations of US$11.84 million and highlights significant operational and regulatory risk factors, including dependence on suppliers, client concentration, cybersecurity and data-protection obligations, heavy PRC regulatory oversight, potential HFCAA-related listing risks, lack of business insurance, and material uncertainties around approvals, licensing and cross-border capital flows.